Clinical Trial Update: AT1001 for the Treatment of Long COVID [Phase 2]

View source ↗

Summary

AT1001 is being evaluated in a Phase 2 trial for Long COVID and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long Covid
• Post-acute COVID-19 Syndrome
• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• AT1001

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Long COVID, Long COVID-19 | Phase 2 | Status: RECRUITING